Provided by Tiger Trade Technology Pte. Ltd.

Longeveron Inc

0.8202
+0.099113.74%
Post-market: 0.84000.0198+2.41%19:59 EDT
Volume:377.68K
Turnover:289.77K
Market Cap:25.55M
PE:-0.73
High:0.8499
Open:0.7200
Low:0.7087
Close:0.7211
52wk High:1.80
52wk Low:0.4750
Shares:31.15M
Float Shares:26.80M
Volume Ratio:0.63
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1195
EPS(LYR):-2.6164
ROE:-135.18%
ROA:-68.00%
PB:1.59
PE(LYR):-0.31

Loading ...

Company Profile

Company Name:
Longeveron Inc
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
38
Office Location:
Life Science & Technology Park,Suite 520,1951 NW 7th Avenue,Miami,Florida,United States
Zip Code:
33136
Fax:
- -
Introduction:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Directors

Name
Position
Joshua M. Hare
Chief Science Officer, Director and Executive Chairman
Stephen Willard
Chief Executive Officer and Director
Deborah Ascheim
Director
George Paletta, Jr.
Director
Leah Rush Cann
Director
Rock Soffer
Director
Roger Hajjar
Director
Ursula Ungaro
Director

Shareholders

Name
Position
Stephen Willard
Chief Executive Officer and Director
Devin Blass
Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing and Controls
Lisa A. Locklear
Chief Financial Officer and Treasurer
Joshua M. Hare
Chief Science Officer, Director and Executive Chairman
Nataliya Agafonova
Chief Medical Officer
Paul Lehr
Corporate Secretary and General Counsel